Skip to main content

Advertisement

SpringerLink
Log in

Comparison of one-year outcomes between as-needed brolucizumab and aflibercept for polypoidal choroidal vasculopathy

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare the one-year visual and anatomic outcomes of an as-needed regimen of brolucizumab and aflibercept for polypoidal choroidal vasculopathy (PCV).

Study design

A retrospective comparative study.

Methods

A retrospective medical chart review was performed for consecutive 56 eyes from 56 patients with PCV initially treated with thee monthly intravitreal aflibercept (n = 33, 2.0 mg/0.05 ml) or brolucizumab (n = 23, 6.0 mg/0.05 ml) followed by as-needed administration, followed up for at least 12 months. All patients were followed up monthly, and fluorescein and indocyanine green angiography (ICGA) were performed at baseline, 3-month, and 12-month visits.

Results

At the 12-month visit, best-corrected visual acuity significantly improved from 0.30 ± 0.31 to 0.21 ± 0.29 (p = 0.042) in the brolucizumab-treated group and from 0.24 ± 0.25 to 0.14 ± 0.25 (p = 7.7×10−3) in the aflibercept-treated group, suggesting comparable visual improvement in both groups. Central retinal thickness and subfoveal choroidal thickness decreased by 38.4% and 14.2%, respectively, in the brolucizumab-treated group and by 34.8% and 13.9%, respectively, in the aflibercept-treated group at the 12-month visit. The mean number of additional injections was significantly higher in the aflibercept-treated group (2.9 ± 2.7) than in the brolucizumab-treated group (1.3 ± 1.2, p = 0.045). The complete resolution of polypoidal lesions on ICGA was higher in the brolucizumab-treated group than in the aflibercept-treated group (3-month visit: 56.5% vs 30.3%, 12-month visit: 56.5% vs 30.3%).

Conclusions

In treatment-naïve eyes with PCV, the as-needed administration regimen of brolucizumab was comparable to aflibercept in terms of visual and anatomical outcomes, with fewer additional injections during the 12-month follow-up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995;15:100–10.

    Article  CAS  PubMed  Google Scholar 

  2. Sakurada Y, Yoneyama S, Sugiyama A, Tanabe N, Kikushima W, Mabuchi F, et al. Prevalence and genetic characteristics of geographic atrophy among elderly Japanese with age-related macular degeneration. PLoS One. 2016;11: e0149978.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, VISiONCT Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–16.

    Article  CAS  PubMed  Google Scholar 

  4. Oishi A, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Nakanishi H, et al. One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am J Ophthalmol. 2015;159:853-860 e1.

    Article  CAS  PubMed  Google Scholar 

  5. Yamamoto A, Okada AA, Kano M, Koizumi H, Saito M, Maruko I, et al. One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology. 2015;122:1866–72.

    Article  PubMed  Google Scholar 

  6. Kikushima W, Sakurada Y, Sugiyama A, Tanabe N, Kume A, Iijima H. Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255:311–6.

    Article  CAS  PubMed  Google Scholar 

  7. Kikushima W, Sakurada Y, Sugiyama A, Yoneyama S, Tanabe N, Matsubara M, et al. Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy. Sci Rep. 2017;7:16461.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Matsumiya W, Honda S, Otsuka K, Miki A, Nagai T, Imai H, et al. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255:541–8.

    Article  CAS  PubMed  Google Scholar 

  9. Morimoto M, Matsumoto H, Mimura K, Akiyama H. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255:1891–7.

    Article  CAS  PubMed  Google Scholar 

  10. Nguyen QD, Das A, Do DV, Dugel PU, Gomes A, Holz FG, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020;127:963–76.

    Article  PubMed  Google Scholar 

  11. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72–84.

    Article  PubMed  Google Scholar 

  12. Ito A, Maruyama-Inoue M, Kitajima Y, Ikeda S, Inoue T, Kadonosono K. One-year outcomes of intravitreal brolucizumab injections in patients with polypoidal choroidal vasculopathy. Sci Rep. 2022;12:7987.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Matsumoto H, Hoshino J, Mukai R, Nakamura K, Akiyama H. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 macular neovascularization. Sci Rep. 2022;12:8195.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Hikichi T. Three Japanese cases of intraocular inflammation after intravitreal brolucizumab injections in one clinic. Jpn J Ophthalmol. 2021;65:208–14.

    Article  CAS  PubMed  Google Scholar 

  15. Kataoka K, Horiguchi E, Kawano K, Ushida H, Nakano Y, Ito Y, et al. Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy. Jpn J Ophthalmol. 2021;65:199–207.

    Article  CAS  PubMed  Google Scholar 

  16. Maruko I, Okada AA, Iida T, Hasegawa T, Izumi T, Kawai M, et al. Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study. Graefes Arch Clin Exp Ophthalmol. 2021;259:2857–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Mukai R, Matsumoto H, Akiyama H. Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. PLoS One. 2021;16: e0259879.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Shigemoto Y, Sakurada Y, Fukuda Y, Matsubara M, Parikh R, Kashiwagi K. The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation. Medicine (Baltimore). 2021;100: e27580.

    Article  CAS  PubMed  Google Scholar 

  19. Hikichi T. Sub-Tenon’s capsule triamcinolone acetonide injection to prevent brolucizumab-associated intraocular inflammation. Graefes Arch Clin Exp Ophthalmol. 2022;260:2529–35.

    CAS  PubMed  Google Scholar 

  20. Fukuda Y, Sakurada Y, Matsubara M, Hasebe Y, Sugiyama A, Kikushima W, et al. Comparison of outcomes between 3 monthly brolucizumab and aflibercept injections for polypoidal choroidal vasculopathy. Biomedicines. 2021;9(9):1164.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Tanaka K, Koizumi H, Tamashiro T, Itagaki K, Nakayama M, Maruko I, et al. Short-term results for brolucizumab in treatment-naive neovascular age-related macular degeneration: a Japanese multicenter study. Jpn J Ophthalmol. 2022;66:379–85.

    Article  CAS  PubMed  Google Scholar 

  22. Schubert W, Terjung C, Rafique A, Romano C, Ellinger P, Rittenhouse KD. Evaluation of molecular properties versus in vivo performance of aflibercept, brolucizumab, and ranibizumab in a retinal vascular hyperpermeability model. Transl Vis Sci Technol. 2022;11:36.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi, 409-3821, Japan

    Yoshiko Fukuda, Yoichi Sakurada, Mio Matsubara, Yumi Kotoda, Yuka Kasai, Atsushi Sugiyama & Kenji Kashiwagi

Authors
  1. Yoshiko Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoichi Sakurada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mio Matsubara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yumi Kotoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuka Kasai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Atsushi Sugiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kenji Kashiwagi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoichi Sakurada.

Ethics declarations

Conflicts of interest

Y. Fukuda, None; Y. Sakurada, None; M. Matsubara, None; Y. Kotoda, None; Y. Kasai, None; A. Sugiyama, None; K. Kashiwagi, None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Corresponding Author: Yoichi Sakurada

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fukuda, Y., Sakurada, Y., Matsubara, M. et al. Comparison of one-year outcomes between as-needed brolucizumab and aflibercept for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 67, 402–409 (2023). https://doi.org/10.1007/s10384-023-00999-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-023-00999-4

Keywords

Search

Navigation